- call +1-201-465-4211
- email sales@mrinsights.biz
Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptoms include bleeding from any site of the body. Internal bleeding is fatal as internal bleeding inside the joint causes joint damage and inside the brain, causes brain damage and seizers. The disease is inherited in an X-linked recessive genetic pattern, therefore males are commonly affected with haemophilia while females are usually carriers of the disease. Haemophilia A is caused by the deficiency of clotting Factor VIII, whereas haemophilia B is caused by the deficiency of Factor IX. It is also known as Christmas disease. The disease management includes factor replacement therapy. Factor replacement therapy is the infusion of factor VIII and IX concentrates through injection to control bleeding. These factor concentrates come from two sources i.e. from human plasma or from genetically engineered cell line made by recombinant DNA technology.
Scope of the Report:
This report studies the Hemophilia A and B Recombinant Factor Replacement Therapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Hemophilia A and B Recombinant Factor Replacement Therapy market by product type and applications/end industries.
The global Hemophilia A and B Recombinant Factor Replacement Therapy market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Hemophilia A and B Recombinant Factor Replacement Therapy.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Pfizer
Novo Nordisk
Baxalta
Bayer
Biogen
CSL Behring
Emergent Biosolutions
Spark therapeutics
Uniqure
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Haemophilia A
Haemophilia B
Market Segment by Applications, can be divided into
Hospitals
Clinics
Ambulatory Surgical Centers
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Hemophilia A and B Recombinant Factor Replacement Therapy Market Overview
1.1 Product Overview and Scope of Hemophilia A and B Recombinant Factor Replacement Therapy
1.2 Classification of Hemophilia A and B Recombinant Factor Replacement Therapy by Types
1.2.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Comparison by Types (2017-2023)
1.2.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share by Types in 2017
1.2.3 Haemophilia A
1.2.4 Haemophilia B
1.3 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market by Application
1.3.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market by Regions
1.4.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Hemophilia A and B Recombinant Factor Replacement Therapy Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Hemophilia A and B Recombinant Factor Replacement Therapy Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Hemophilia A and B Recombinant Factor Replacement Therapy Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Hemophilia A and B Recombinant Factor Replacement Therapy Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Hemophilia A and B Recombinant Factor Replacement Therapy Status and Prospect (2013-2023)
1.5 Global Market Size of Hemophilia A and B Recombinant Factor Replacement Therapy (2013-2023)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 Hemophilia A and B Recombinant Factor Replacement Therapy Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novo Nordisk
2.2.1 Business Overview
2.2.2 Hemophilia A and B Recombinant Factor Replacement Therapy Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.3 Baxalta
2.3.1 Business Overview
2.3.2 Hemophilia A and B Recombinant Factor Replacement Therapy Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.4 Bayer
2.4.1 Business Overview
2.4.2 Hemophilia A and B Recombinant Factor Replacement Therapy Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.5 Biogen
2.5.1 Business Overview
2.5.2 Hemophilia A and B Recombinant Factor Replacement Therapy Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.6 CSL Behring
2.6.1 Business Overview
2.6.2 Hemophilia A and B Recombinant Factor Replacement Therapy Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.7 Emergent Biosolutions
2.7.1 Business Overview
2.7.2 Hemophilia A and B Recombinant Factor Replacement Therapy Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.8 Spark therapeutics
2.8.1 Business Overview
2.8.2 Hemophilia A and B Recombinant Factor Replacement Therapy Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.9 Uniqure
2.9.1 Business Overview
2.9.2 Hemophilia A and B Recombinant Factor Replacement Therapy Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, Gross Margin and Market Share (2016-2017)
3 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Competition, by Players
3.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Hemophilia A and B Recombinant Factor Replacement Therapy Players Market Share
3.2.2 Top 10 Hemophilia A and B Recombinant Factor Replacement Therapy Players Market Share
3.3 Market Competition Trend
4 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Regions
4.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Market Share by Regions
4.2 North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
4.3 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
4.5 South America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
5 North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Countries
5.1 North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Countries (2013-2018)
5.2 USA Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
5.3 Canada Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
5.4 Mexico Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
6 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Countries
6.1 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Countries (2013-2018)
6.2 Germany Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
6.3 UK Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
6.4 France Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
6.5 Russia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
6.6 Italy Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Countries
7.1 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Countries (2013-2018)
7.2 China Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
7.3 Japan Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
7.4 Korea Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
7.5 India Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
8 South America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Countries
8.1 South America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Countries (2013-2018)
8.2 Brazil Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
8.3 Argentina Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
8.4 Colombia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Hemophilia A and B Recombinant Factor Replacement Therapy by Countries
9.1 Middle East and Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Countries (2013-2018)
9.2 Saudi Arabia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
9.3 UAE Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
9.4 Egypt Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
9.5 Nigeria Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
9.6 South Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Growth Rate (2013-2018)
10 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Segment by Type
10.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue and Market Share by Type (2013-2018)
10.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Forecast by Type (2018-2023)
10.3 Haemophilia A Revenue Growth Rate (2013-2023)
10.4 Haemophilia B Revenue Growth Rate (2013-2023)
11 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Segment by Application
11.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share by Application (2013-2018)
11.2 Hemophilia A and B Recombinant Factor Replacement Therapy Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)
11.5 Ambulatory Surgical Centers Revenue Growth (2013-2018)
12 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Forecast (2018-2023)
12.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Forecast (2018-2023)
12.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Forecast by Regions (2018-2023)
12.3 North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Forecast (2018-2023)
12.4 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Forecast (2018-2023)
12.6 South America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Hemophilia A and B Recombinant Factor Replacement Therapy Picture
Table Product Specifications of Hemophilia A and B Recombinant Factor Replacement Therapy
Table Glo
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
